Metabolic Syndrome and Obstructive Sleep Apnoea Hypopnea Syndrome
Conditions
Interventions
Group A (control group):none
Group B(Metabolic Syndrome group):none
Group C (Obstructive Sleep Apnoea Hypopnea Syndrome group):none
Group D ( Metabolic Syndrome comorbid with Obstructive Sleep Apnoea Hypopnea Syndrome group):none
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Group A (control group): 1) Aged 18-75 years and any gender; 2) Does not meet OSA diagnostic criteria; 3) Does not meet MS diagnostic criteria; 4) The Generalized Anxiety Disorder-7 (GAD-7) score <10; 5) The Patient Health Questionnaire-9 (PHQ-9) score <10; 5) Signed informed consent form. All inclusion criteria must be satisfied. Group B (Metabolic Syndrome group): 1) Aged 18-75 years any gender; 2) Confirmed OSA diagnosis; 3) Does not meet MS diagnostic criteria; 4) The GAD-7 score <10; 5) The PHQ-9 score <10; 6) Signed informed consent form. All inclusion criteria must be satisfied. Group C (Obstructive Sleep Apnoea Hypopnea Syndrome group): 1) Aged 18-75 years any gender; 2) Does not meet OSA diagnostic criteria; 3) Confirmed MS diagnosis; 4) The GAD-7 score <10; 5) ThePHQ-9 score <10; 6) Signed informed consent form. All inclusion criteria must be satisfied. Group D (Metabolic Syndrome comorbid with Obstructive Sleep Apnoea Hypopnea Syndrome group): 1) Aged 18-75 years any gender; 2) Confirmed OSA diagnosis; 3) Confirmed MS diagnosis; 4) The GAD-7 score <10; 5) The PHQ-9 score <10; 6) Signed informed consent form. All inclusion criteria must be satisfied.
Exclusion criteria
Exclusion criteria: Group A: 1) Comorbid severe diseases (serious diseases of the neurological respiratory digestive endocrine or immune systems); clinically diagnosed organic diseases or history of cardiovascular diseases (e.g. coronary heart disease heart failure arrhythmias) either through medical records or self-reported symptoms. 2) Medications that may affect the results (have an impact on the cardiac function of volunteers) taken in the recent two weeks such as weight loss products that may contain caffeine ephedrine and other ingredients and Chinese herbal medicines such as ginseng and licorice that may affect blood pressure and heart rate; 3) Intellectual disability substance abuse/dependence (including alcohol) or other psychiatric disorders. 4) Pregnant or lactating women. 5) Implanted metal devices or cardiac pacemakers or other contraindications preventing completion of required assessments. Group B 1) Comorbid severe diseases (serious diseases of the neurological respiratory digestive endocrine or immune systems) orclinically diagnosed organic diseases; 2) Medications that may affect the results (have an impact on the cardiac function of volunteers) taken in the recent two weeks such as weight loss products that may contain caffeine ephedrine and other ingredients and Chinese herbal medicines such as ginseng and licorice that may affect blood pressure and heart rate; 3) Intellectual disability substance abuse/dependence or psychiatric comorbidities; 4) Current pregnancy or lactation; 5) Implanted metal devices or cardiac pacemakers or other contraindications preventing completion of required assessments. Group C 1) Comorbid severe diseases (serious diseases of the neurological respiratory digestive endocrine or immune systems) orclinically diagnosed organic diseases; 2) Medications that may affect the results (have an impact on the cardiac function of volunteers) taken in the recent two weeks such as weight loss products that may contain caffeine ephedrine and other ingredients and Chinese herbal medicines such as ginseng and licorice that may affect blood pressure and heart rate; 3) Diagnosed neurodevelopmental/psychiatric disorders with substance misuse; 4) Pregnancy or breastfeeding status. 5) Metallic implants/cardiac devices or assessment contraindications. Group D: 1) Comorbid severe diseases (serious diseases of the neurological respiratory digestive endocrine or immune systems) orclinically diagnosed organic diseases; 2) Medications that may affect the results (have an impact on the cardiac function of volunteers) taken in the recent two weeks such as weight loss products that may contain caffeine ephedrine and other ingredients and Chinese herbal medicines such as ginseng and licorice that may affect blood pressure and heart rate; 3) Comorbid psychiatric conditions (intellectual disability substance use disorders). 4) Pregnancy or breastfeeding status. 5) Metallic implants/cardiac devices or assessment contraindications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac magnetic signal; | — |
Secondary
| Measure | Time frame |
|---|---|
| Constitution in Chinese Medicine Questionnaire;Fasting Blood Glucose (FBG);Pulse to respiratory ratio;Tumor Necrosis Factor (TNF-a);Lipid Profile (Total Cholesterol Triglycerides HDL LDL);Hemoglobin A1c (HbA1c);Deficiency/Excess Syndrome Evaluation Scale of Chinese Medicine;Interleukin-6 (IL-6);Electrocardiogram (ECG);Fasting Insulin;C-Reactive Protein (CRP);Dampness Syndrome Scale of Chinese Medicine; | — |
Countries
China
Contacts
Public ContactZhimin Yang
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed